Log in or register to see all Alerts
New HTA Decisions in Scotland
December 2019
Drug name
CYRAMZA® (ramucirumab)
Company
Eli Lilly and Company Ltd
Decision date
11/11/2019
Therapeutic area
Cancer
Therapeutic sub area
Liver cancers
Decision
Not recommended
Indication
As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of ≥400 ng/mL and who have been previously treated with sorafenib.
Decision Detail
In the absence of a submission from the holder of the marketing authorisation, ramucirumab (CYRAMZA®) is not recommended for use within NHS Scotland.
Summary
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result the SMC cannot recommend its use within NHS Scotland.